usps-logo.jpg?1721728722
Ultrafast Ultrasonic Synthesis
Catalog peptides: immediate delivery
ISO 9001/2015 certified
1000 peptides & peptide pools
30 years of experience in peptide synthesis

EBV BARF1 Peptide Pool



Pool of 53 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Secreted protein BARF1 (UniProt: P03225) of Homo sapiens Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4).

One unit allows the stimulation of 2,5 x 108 cells.

FAQs
No search results.

For long-term storage, we recommend to store the peptides in lyophilized form at -20°C, or preferably at -80°C in sealed containers to minimize peptide degradation. Under these conditions, peptides can be stored for up to several years and this prevents different kinds of degradation such as oxidation, formation of secondary structures and bacterial contamination. The shelf stability of peptides is sequence-dependent. Sequences containing cysteine, methionine, tryptophan, asparagine, glutamine and N-terminal glutamic acid will have a shorter shelf life than other peptides. For short-time storage, we recommend to store the peptides in a refrigerator (+4°C). The peptides should be protected from direct sunlight and peptides with fluorophores should be stored in darkness.

Before opening the peptides, it is better to equilibrate to room temperature as peptides tend to be hygroscopic and can lead to cause condensation. Condensation can reduce the stability of the peptides. Before using the peptides, we recommend centrifuging them.

Dissolved peptides are less stable than lyophilized peptides and shouldn’t be stored long-term. We recommend to lyophilize the dissolved peptides.

Basic buffers should be avoided for peptides containing disulfide bridges. The disulfide bond is formed quickly at a neutral and slightly basic pH. However, the disulfide bond is reversible and can be reduced with DTT at basic conditions. The optimum pH-range is between 7.0-9.5. Due to the easy oxidation of DTT, the solution should be freshly prepared. Peptides containing free thiol groups may oxidize to form dimers or oligomers during storage, including the lyophilized form at a low temperatures. Peptides provided as acetate salts are more sensitive to cysteine oxidation than the corresponding TFA salt or HCl salt.
Peptides containing a single free cysteine will be oxidized at pH>7 to form dimers. This oxidation can be reverted. Peptides containing two or more thiol moieties may yield a mixture of products upon oxidation. The pH 7.5-8 is the best condition for disulfide bond formation. Hence, peptides containing free cysteines are best dissolved in degassed solvents, e.g. buffers pH<7, diluted acetic acid, 0.1% trifluoroacetic acid in aqueous acetonitrile. DMSO should be avoided, especially with peptide trifluoroacetates.

Unfortunately, it is not possible to predict if a peptide is water-soluble by studying its structure alone, but there are clues for determining solubility, especially for short peptides. The ε-amino group of Lysine and the guanidine group of Arginine are in pronated form in peptides sold as TFA salts and are easily dissolved in water. Peptides containing many acidic amino acids such as aspartic acid and glutamic acid, however, are difficult to dissolve in water but are readily soluble with ammonia or basic buffers.

Here you will find certain basic characteristics to predict solubility:

  • Short peptides with <5 amino acids are usually highly soluble in aqueous solutions. However, if the peptides contain only hydrophobic amino acids, they may be difficult or impossible to dissolve in water.
  • Peptides with many hydrophilic amino acids (>25%) (E,D,K,R,H) and few hydrophobic amino acids (<25%) are usually well soluble in aqueous solutions.
  • Peptides containing ≥50% hydrophobic amino acids should be well or partially soluble in aqueous solutions. If the peptides are only partially soluble, organic solvents such as DMSO, DMF, acetonitrile, isopropyl alcohol, ethanol, acetic acid, 4-8 M guanidine hydrochloride (GdnHCl), or urea should be used and further diluted with aqueous solutions. However, peptides containing C, M or W should not be dissolved in DMSO due to oxidation reactions.
  • Hydrophobic peptides with more than 75% hydrophobic amino acids are usually not soluble in water. For these peptides, strong solvents such as TFA or formic acid should be used for dissolution. Dilution with an aqueous solution could again lead to precipitation of the peptide. Therefore, high concentrations of organic solvents or denaturants may be necessary to completely dissolve the peptide.
  • Peptides containing a very high proportion (>75%) of the following amino acids: D, E, H, K, N, Q, R, S, T, or Y can form intermolecular hydrogen bonds, which leads to gel formation in aqueous solutions. Such peptides are best dissolved with organic solvents. Dilution with aqueous solutions should only be done dropwise. The limit of aqueous solubility can be recognized by the turbidity of the solution.
Gene:BARF1
Delivery:overnight
Counter Ion:TFA
Protein:Secreted protein BARF1
UniProt Id:P03228
Species:Epstein-Barr virus (strain B95-8) (HHV-4) (Human herpesvirus 4)

Bosc-Bierne, G et al. „Efficient Quality Control of Peptide Pools by UHPLC and Simultaneous UV and HRMS Detection. Separations 2024, 11, 156. https://doi.org/10.3390/separations11050156

Lin, Yusheng et al. “VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses.” Experimental hematology & oncology vol. 13,1 35. 29 Mar. 2024, doi:10.1186/s40164-024-00501-x

Kim, Sang-Hoon et al. “Omicron BA.2 breakthrough infection elicits CD8+ T cell responses recognizing the spike of later Omicron subvariants.”
Science immunology vol. 9,91 (2024): eade6132. doi:10.1126/sciimmunol.ade6132

€201.25*

Delivery time 2-3 days
sterile and endotoxin free
Delivery Format: The product is supplied freeze dried.
Product number: LB02234

Controls

HUMAN Tyrosinase Peptide Pool
Pool of 130 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Tyrosinase (Swiss-Prot ID: P14679) of Homo sapiens (Human) for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€217.35*
Tip
Tetanus Toxin Peptide Pool
Peptide pool of 326 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Tetanus toxin (UniProt ID: P04958) of Clostridium tetani (strain Massachusetts / E88) for T cell assays (e.g. ELISPOT) One unit allows the stimulation of 2,5 x 108 cells.

€362.25*
Tip
HCMVA (pp65) Peptide Pool
Peptide Pool of 138 peptides derived from a peptide scan (15mers with 11 aa overlap) through 65 kDa phosphoprotein (pp65) (UniProtKB - P06725) of Human cytomegalovirus (HHV-5). Frequently used as positive control. One unit allows the stimulation of 2,5 x 108 cells. You can find applications and references in our blog: FACS analysis showed: CMV-specific T cells respond to leukemia antigen >

€187.20*
HUMAN Tyrosinase-related protein2 Peptide Pool
Pool of 127 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through L-dopachrome tautomerase (Tyrosinase-related protein 2) (Swiss-Prot ID: P40126) of Homo sapiens (Human). One unit allows the stimulation of 2,5 x 108 cells.

€217.35*
CEF (classic) Peptide Pool (>95% HPLC)
The CEF peptide pool is a lyophilized mixture of 23 peptides from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and influenza virus . It consists of defined HLA class I-restricted T cell epitopes from these three viruses, and can be used as a positive control to stimulate T cells. The CEF peptide pool is used as a positive control to stimulate T cells. It induces secretion of e.g., IFN-γ, IL-2, and granzyme B from human CD8 T cells . The peptides of this product are supplied as trifluoracetate salts. One unit allows the stimulation of 2,5 x 108 cells.

€96.00*
HUMAN Melan-A/MART-1 Peptide Pool
Pool of 27 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Melanoma antigen recognized by T-cells 1 (MART-1) (UniProt ID: Q16655) of Homo sapiens (Human) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€181.15*
Meso GPI (271-630) Sub Peptide Pool
Pool of 88 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Mesothelin (aa271-aa630) of homo sapiens One unit allows the stimulation of 2,5 x 108 cells.

€181.15*
JC polyomavirus (VP1) Peptide Pool
Pool of 86 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Major capsid protein VP1 (UniProt ID: P03089) of JC polyomavirus (JCPyV) (JCV) for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€211.35*
HUMAN WT1 Peptide Pool
Peptide pool of 110 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Wilms tumor protein (WT33) (Swiss-Prot ID: P19544) of Homo sapiens (Human) for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells. You can find applications and references in our blog: FACS analysis showed: CMV-specific T cells respond to leukemia antigen >

€217.35*

Related Pools

HUMAN Tyrosinase Peptide Pool
Pool of 130 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Tyrosinase (Swiss-Prot ID: P14679) of Homo sapiens (Human) for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€217.35*
HUMAN AFP Peptide Pool
Pool of 150 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Alpha-fetoprotein (Swiss-Prot ID: P02771) of Homo sapiens for T cell assays (e.g. ELISPOT). One unit allows the stimulation of 2,5 x 108 cells.

€289.80*
HUMAN LAGE1 (CTAG2) Peptide Pool
Pool of 50 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Cancer/testis antigen 2 (UniProt ID: O75638) of Homo sapiens (Human) for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€181.15*
HPV (BK-Virus LT) Peptide Pool
Pool of 171 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Large T antigen (UniProtKB - P03071) of BK polyomavirus for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€289.80*
EBV (EBNA-3b) Peptide Pool
Pool of 234 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Epstein-Barr nuclear antigen 4 (EBNA3b) (UniProt ID: Q1HVG4) of Epstein-Barr virus (HHV4) for T cell assays. One unit allows the stimulation of 2,5 x 108 cells.

€229.45*
HHV6 (U54) Peptide Pool
Pool of 112 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through U54 (UniProt ID: Q9QJ29) of Human herpesvirus 6B for T cell assays (antigen specific T-cell stimulation). One unit allows the stimulation of 2,5 x 108 cells.

€211.35*
HIV control Peptide Pool (95% HPLC)
The peptides of this product are supplied as trifluoracetate salts. This pool consists of 22 peptides, each corresponding to a defined HLA class I-restricted T cell epitope from human immunodeficiency virus (HIV). One unit allows the stimulation of 2,5 x 108 cells.

€181.15*
HBV Protein P Peptide Pool
Pool of 209 overlapping peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein P (UniProt ID: Q9WRL0) of Hepatitis B virus (HBV) One unit allows the stimulation of 2,5 x 108 cells.

€241.50*

Relatated Petides

EBV LMP2 131-139 (HLA-A*24:02) ( PYLFWLAAI )
Amount in mg: 1 mg
Single peptide (PYLFWLAAI) for stimulation of human EBV LMP2(131-139)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*2402 allele.

€60.40*
EBV EBNA-3A 379-387 (HLA-B*07:02) ( RPPIFIRRL )
Amount in mg: 1 mg
Antigen Peptide EBV EBNA3A HLA-B*07:02 (RPPIFIRRL) for stimulation of human EBV EBNA-3A (379-387) specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*0702 allele.

€60.40*
HCMV pp65 417 – 426 (HLA-B*07:02) ( TPRVTGGGAM )
Amount in mg: 1 mg
Antigen Peptide CMV pp65 - HLA-B*07:02 (TPRVTGGGAM) for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxity or proliferation assays. CMV pp65 (415-429) (HLA-B7) is a CEF control peptide that is derived from the Cytomegalovirus (CMV). CMV is capable of infecting a wide range of human cell types, where the body’s primary immune response to CMV is innate, and relies on inflammatory cytokines and costimulatory molecules in order to control the spread of the virus. CMV pp65 (415-429) (HLA-B7) is defined as a CEF control peptide due to its antigenic properties. Clinically, these peptides are suitable epitopes for CD8+ T cells and can be used to stimulate the release of IFNg. HLA-B7 refers to the cell HLA type that this peptide acts on.

€120.75*
HCMV IE-1 316-324 (HLA-A*02:01) ( VLEETSVML )
Amount in mg: 1 mg
Antigen Peptide CMV IE1 HLA-A*02:01 (VLEETSVML) stimulation of human CMV IE-1(316-324)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*02:01 allele.

€60.40*
EBV BMLF-1 280-288 (HLA-A*02:01) ( GLCTLVAML )
Amount in mg: 1 mg
EBV peptide GLCTLVAML (HLA-A*0201) for stimulation of T-cells. Single peptide (GLCTLVAML) for stimulation of human EBV BMLF-1(280-288) CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*0201 allele.

€60.40*
RHAMM 165-173 (HLA-A*02:01) ( ILSLELMKL )
Amount in mg: 1 mg
RHAMM peptide ILSLELMKL (HLA-A*02:01) for stimulation of human RHAMM -specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*02:01 allele.

€60.40*
HPV 16 E7 49-57 (H-2 Db) ( RAHYNIVTF )
Amount in mg: 1 mg
RAHYNIVTF is a linear peptidic epitope studied as part of Protein E7 from Alphapapillomavirus 9 and Other Human papillomavirus protein from Human papillomavirus. This epitope is used for immune reactivity in, T cell assays, B cell assays and MHC ligand assays. HPV 16 E7(49-57) peptide RAHYNIVTF (H-2 Db) for stimulation of mouse HPV 16 E7 (49-57)-specific CD8+ T cells. The peptide is synthesised as it is presented by the MHC class I H-2 Db allele.

€60.40*

DYN-Test

AAV VP1 492-500 (HLA-A*01:01) ( SADNNNSEY )
#

From €60.40*
ADV hexon (HLA-B*35:01) ( MPNRPNYIAF )
ADV hexon peptide MPNRPNYIAF (HLA-B*35:01) for stimulation of T-cells. Single peptide (MPNRPNYIAF) for stimulation of human ADV hexon-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*35:01 allele

From €60.40*
ADV hexon 114 -124 (HLA-B*07:02) ( KPYSGTAYNAL )
Single peptide (KPYSGTAYNAL) for stimulation of human ADV Hexon (114-124)-specific CD8+ T cells. The peptide is synthesised as it is presented by the MHC class I HLA-B*07:02 allele. Lyophilized powder. Purity > 95 %, endotoxin free.

From €60.40*
ADV hexon 37-45 (HLA-A*24:02) ( TYFSLNNKF )
Single peptide (TYFSLNNKF) for stimulation of human ADV Hexon (37-45)-specific CD8+ T cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*24:02 allele. Lyophilized powder. Purity > 95 %, endotoxin free.

From €60.40*
ADV Hexon 917-925 (HLA-A*02:01) ( YVLFEVFDV )
Single peptide (YVLFEVFDV) for stimulation of human ADV Hexon (917-925)-specific CD8+ T cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*02:01 allele. Lyophilized powder. Purity > 95 %, endotoxin free.

From €60.40*
BA46 194-202 (HLA-A*02:01) ( NLFETPVEA )
This peptide has a high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This peptide NLFETPVEA is covering 194-202 and is presenting MHC-Class I HLA- A*02:01.

From €60.40*
BA46 97-106 (HLA-A*02:01) ( GLQHWVPEL )
This gene encodes a preproprotein that is proteolytically processed to form multiple protein products. The major encoded protein product, lactadherin, is a membrane glycoprotein that promotes phagocytosis of apoptotic cells. This protein has also been implicated in wound healing, autoimmune disease, and cancer. Lactadherin can be further processed to form a smaller cleavage product, medin, which comprises the major protein component of aortic medial amyloid (AMA). Alternative splicing results in multiple transcript variants.

From €60.40*
BAP31 167-175 (HLA-A*02:01) ( KLDVGNAEV )
KLDVGNAEV is a linear peptidic epitope (epitope ID445492) studied as part of B-cell receptor-associated protein 31 from Homo sapiens (human). This epitope has been studied for immune reactivity and tested in MHC ligand assays

From €60.40*
BCL-2 180-189 (HLA-A*02:01) ( YLNRHLHTWI )
This peptide has high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide/MHC complex composed BCL-2-derived peptide of YLNRHLHTWI sequence covering 180-189 and A*02:01 molecule.

From €60.40*
BCL-2 208-217 (HLA-A*02:01) ( PLFDFSWLSL )
This peptide has high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide/MHC complex composed BCL-2-derived peptide of PLFDFSWLSL sequence covering 208-217 and A*02:01 molecule.

From €60.40*
Bcl-2 214-223 (HLA-A*02:01) ( WLSLKTLLSL )
Bcl-2 peptide WLSLKTLLSL (HLA-A*0201) is a single peptide for stimulation of T cells. The peptide from B cell lymphoma 2 (Bcl-2) is synthesized as it is presented by the MHC class I HLA-A*0201 allele and can be used for targeted in vitro generation and expansion of antigen-specific CD8+ T cells.

From €60.40*
BCL-2 85-93 (HLA-A*02:01) ( ALSPVPPVV )
#

From €60.40*
BCL-2A1 15-23 (HLA-A*24:02) ( DYLQYVLQI )
This peptides are used for the detection of antigen-specific T-cell populations. MHC-peptide tetramer complexes recognize antigen specific T-cells at the single cell level, allowing for accurate measurements of the functional immune response in cancer, infectious diseases, and autoimmune diseases.ï¾  Due to their increased avidity, MHC tetramers stably bind to cognate TcRs and are evaluated using flow cytometry.

From €60.40*
BCL-2L1 165-173 (HLA-A*03:01) ( RIAAWMATY )
#

From €60.40*
BCL2-like 1 173-182 (HLA-A*02:01) ( YLNDHLEPWI )
This peptides has a high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide/MHC complex composed BCL-X-derived peptide of YLNDHLEPWI sequence covering 173-182 and A*02:01 molecule.

From €60.40*
BCR-ABL (HLA-A*02:01) ( GVRGRVEEI )
#

From €60.40*
BCR-ABL 19-27 (HLA-B*27:01) ( GFKQSSKAL )
Tumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assayTumor Antigen-derived Peptide. GFKQSSKAL is a linear peptidic epitope (epitope ID19558) studied as part of Other Homo sapiens (human) protein from Homo sapiens (human), tested in MHC ligand assay

From €60.40*
BCR-ABL 926-934 (HLA-A*02:01) ( SSKALQRPV )
#

From €60.40*
BCR/ABL 210 kD fusion protein 259-269 (HLA-A*03:01) (HLA-A*11:01) ( ATGFKQSSK )
This peptide has high avidity for CD8 T cells, and can be used in the analysis of individual antigen-specific T cells. This product is a MHC pentamer of peptide composed BCR-ABL 210 kD fusion protein-derived peptide of ATGFKQSSK sequence covering 259-269 and A*03:01, A*11:01 molecule.

From €60.40*
BGLAP (HLA-A*24:02) ( LYQWLGAPV )
#

From €60.40*
BGLAP 1-10 (HLA-A*02:01) ( YLYQWLGAPV )
#

From €60.40*
BKV Large T antigen 579-587 (HLA-A*02:01) ( LLLIWFRPV )
BKV LT-ag peptide LLLIWFRPV (HLA-A*02:01) for stimulation of human BKV LT-ag(579-587)-specific CD8+ T-cells. The peptide is synthesised as it is presented by the MHC class I HLA-A*02:01 allele. LLLIWFRPV is a linear peptidic epitope (epitope ID37507) studied as part of Human polyomavirus 1 (polyomavirus BK) protein from Human polyomavirus 1 (BK polyomavirus). This epitope has been studied for immune reactivity, tested in T cell assays and MHC ligand assay.

From €60.40*
BKV Large T antigen 406-414 (HLA-A*02:01) ( VIFDFLHCI )
VIFDFLHCI is a linear peptidic epitope (epitope ID 68945 ) studied as part of Human polyomavirus 1 protein from Human polyomavirus 1. This epitope has been studied for immune reactivity and was tested in T cell assays and MHC ligand assay

From €60.40*